Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019040969) COMPOSITIONS, DEVICES AND METHODS FOR TREATING OBSESSIVE-COMPULSIVE DISORDER
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/040969 International Application No.: PCT/AU2018/000160
Publication Date: 07.03.2019 International Filing Date: 31.08.2018
IPC:
A61K 31/437 (2006.01) ,A61K 31/496 (2006.01) ,A61K 31/454 (2006.01) ,A61K 31/495 (2006.01) ,A61P 25/00 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
4353
ortho- or peri-condensed with heterocyclic ring systems
437
the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
496
Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
44
Non-condensed pyridines; Hydrogenated derivatives thereof
445
Non-condensed piperidines, e.g. piperocaine
4523
containing further heterocyclic ring systems
454
containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25
Drugs for disorders of the nervous system
Applicants:
CENTRE FOR DIGESTIVE DISEASES [AU/AU]; Level 1 229 Great North Road Five Dock, NSW 2046, AU
Inventors:
BORODY, Thomas Julius; AU
Agent:
SPRUSON & FERGUSON; GPO Box 3898 Sydney, New South Wales 2001, AU
Priority Data:
62/552,51731.08.2017US
Title (EN) COMPOSITIONS, DEVICES AND METHODS FOR TREATING OBSESSIVE-COMPULSIVE DISORDER
(FR) COMPOSITIONS, DISPOSITIFS ET PROCÉDÉS POUR LE TRAITEMENT DU TROUBLE OBSESSIONNEL COMPULSIF
Abstract:
(EN) The present invention relates to a method for treating, ameliorating, reversing and/or preventing an obsessive-compulsive disorder (OCD) via the administration of a formulation, a pharmaceutical preparation or a pharmaceutical composition comprising or consisting of: (a) a rifaximin (optionally a XIFAXAN, XIFAXANTA or NORMIXT), an extended intestinal release (EIR) rifaximin, a rifamycin derivative, a rifampicin (or rifampin) (optionally RIFADIN), a rifabutin (optionally MYCOBUTIN), a rifapentine (optionally PRIFTIN), a rifalazil, a bicozamycin, a pyrido-imidazo rifamycin, or a mixture or combination thereof, or (b) a rifaximin, a polymorphic form of a rifaximin, or rifaximin equivalent thereof (optionally a XIFAXAN, XIFAXANTA or NORMIX) and at least one additional antimicrobial or antibiotic agent.
(FR) La présente invention concerne un procédé de traitement, d'amélioration, d'inversion et/ou de prévention d'un trouble obsessionnel compulsif (OCD) par l'administration d'une formulation, d'une préparation pharmaceutique ou d'une composition pharmaceutique comprenant ou constituée par : (a) une rifaximine (facultativement un XIFAXAN, un XIFAXANTA ou un NORMIXT), une rifaximine à libération intestinale étendue (EIR), un dérivé de rifamycine, une rifampicine (ou rifampine) (facultativement RIFADIN), un rifabutine (facultativement MYCOBUTIN), une rifapentine (facultativement PRIFTIN), un rifalazil, une bicozamycine, une pyrido-imidazorifamycine ou un mélange ou une combinaison correspondant ou (b) une rifaximine, une forme polymorphe d'une rifaximine ou un équivalent de rifaximine correspondants (facultativement un XIFAXAN, un XIFAXANTA ou un NORMIX) et au moins un agent antimicrobien ou antibiotique supplémentaire.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)